Clinical trial
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study
NCT04660760 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 Study
- Lead sponsor
- Academic and Community Cancer Research United
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 16, 2021
- Completion date
- May 31, 2026
- Enrollment
- 116 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv gastric cancer ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva gastric cancer ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ivb gastric cancer ajcc v8, clinical stage ivb gastroesophageal junction adenocarcinoma ajcc v8, locally advanced unresectable gastric adenocarcinoma, locally advanced unresectable gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, pathologic stage iii gastric cancer ajcc v8, pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia gastric cancer ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib gastric cancer ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiic gastric cancer ajcc v8, pathologic stage iv gastric cancer ajcc v8, pathologic stage iv gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ivb gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii gastric cancer ajcc v8, postneoadjuvant therapy stage iii gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv gastric cancer ajcc v8, postneoadjuvant therapy stage iv gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb gastroesophageal junction adenocarcinoma ajcc v8